A5064222978- Trypanosoma species research and implications
- Research on Leishmaniasis Studies
- Synthesis and Biological Evaluation
- Insect symbiosis and bacterial influences
- Parasites and Host Interactions
- Parasitic Diseases Research and Treatment
- Galectins and Cancer Biology
- Fungal Infections and Studies
- Celiac Disease Research and Management
- Venomous Animal Envenomation and Studies
- Helicobacter pylori-related gastroenterology studies
- Plant Pathogens and Fungal Diseases
- Antifungal resistance and susceptibility
- Public Health and Environmental Issues
- Intestinal Malrotation and Obstruction Disorders
- Infectious Diseases and Mycology
- Macrophage Migration Inhibitory Factor
- HIV Research and Treatment
- Endometrial and Cervical Cancer Treatments
- Eosinophilic Disorders and Syndromes
- Pancreatitis Pathology and Treatment
- Rabies epidemiology and control
- Public Health and Social Inequalities
- Coenzyme Q10 studies and effects
- Microscopic Colitis
Administración Nacional de Laboratorios e Institutos de Salud
2016-2025
Ministerio de Salud
2018-2024
Hospital Muñiz
2017-2023
Institute of Parasitology
2019
Hospital de León
2005
Celiac disease (CD) is a common disorder in children and adults. However, limited data are available when comparing differences between both populations.To prospectively evaluate compare the clinical histological features present at diagnosis cohort of celiac adults.Consecutive new cases diagnosed 2000 2006 were included (66 54 adults). The spectrum was categorized two groups: (a) typical (malabsorption, chronic diarrhea, or failure to thrive) (b) oligosymptomatic (abdominal pain, anemia,...
ABSTRACT There is a clinical need to test new schemes of benznidazole administration that are expected be at least as effective the current therapeutic scheme but safer. This study assessed in chronic Chagas disease patients. A pilot with intermittent doses 5 mg/kg/day two daily every days for total 60 was designed. The main criterion response comparison quantitative PCR (qPCR) findings prior and 1 week after end treatment. safety profile by rate suspensions severity adverse effects. Twenty...
Abstract Background Chagas disease (CD) continues to be a neglected infectious with one of the largest burdens globally. Despite modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still drug choice. Its current recommended dose based on nonrandomized studies, efficacy optimal BNZ have been scarcely analyzed clinical trials. Methods/design MULTIBENZ phase II, randomized, superiority, double-blind, multicenter international trial. A total 240 Trypanosoma...
A case of tinea corporis by Trichophyton indotineae observed in Argentina is presented. The patient had a history having spent 18 months Tulum, Mexico. She was suffering from the anterior region both thighs and gluteal area. mycological study performed T. mentagrophytes complex isolated. fungus later identified as DNA sequencing treatment with SUBA-itraconazole initiated good clinical response.
Benznidazole (BNZ) is the primary treatment for Chagas disease. While pharmacokinetic studies of BNZ began in 1970s, its metabolism and excretion are not fully understood. Alternatives like Benznidazol Lafepe® Abarax® have replaced original Radanil®. To compare profiles both currently available formulations adults with chronic Trypanosoma cruzi infection. The study involved 13 subjects each one receiving 100 mg presentations week apart. Blood samples were collected over 48 hours...
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children all stages, but it controversial chronically infected adults. We report the pharmacokinetics and pharmacodynamics six adult patients treated new BNZ formulation (ABARAX®) doses between 2.5-5.5 mg/Kg/day. All one patient had plasmatic concentrations within expected range. finalised nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained at month follow-up. Our data...
A Trypanosoma cruzi Loopamp kit was recently developed as a ready-to-use diagnostic method requiring minimal laboratory facilities. We evaluated its accuracy for detection of acute Chagas disease (CD) in different epidemiological and clinical scenarios. In this retrospective study, convenience series samples (venous blood treated with EDTA or stabilizer agents, heel-prick filter paper cerebrospinal fluid (CSF)) from 30 infants born to seropositive mothers (13 congenital CD 17 noninfected),...
Background. In contrast to adults, Trypanosoma cruzi-infected children have more broadly functional cruzi-specific T cells, and the total T-cell compartment exhibits fewer signs of immune exhaustion. However, not much is known about link between immunocompetence treatment efficacy for human Chagas disease. Methods. Using cytokine enzyme-linked immunosorbent spot (ELISPOT) polychromatic flow cytometry, cytometric bead assay, multiplex serological assays quantitative PCR, we evaluated T....
In a pilot study, we showed that the intermittent administration of benznidazole in chronic Chagas disease patients resulted low rate treatment suspension and therapeutic failure, as assessed by quantitative PCR (qPCR) at end treatment. Here, 3-year posttreatment follow-up study same cohort is presented. The scheme consisted 12 doses 5 mg/kg body weight/day two daily every days. Parasite load, Trypanosoma cruzi -specific antibodies, serum chemokine levels were measured prior to after median...
Objective Chagas disease (CD) globalization facilitated the co-infection with Human Immunodeficiency Virus (HIV) in endemic and non-endemic areas. Considering underestimation of Trypanosoma cruzi (T . cruzi) -HIV risk life-threatening Disease Reactivation (CDR), this study aimed to analyze major clinical characteristics its mortality rates. Methods This is a cross-sectional retrospective multicenter patients CD confirmed by two serological or one parasitological tests, HIV infection...
A loop-mediated isothermal amplification assay was evaluated as a surrogate marker of treatment failure in Chagas disease (CD). convenience series 18 acute or reactivated CD patients who received anti-parasitic with benznidazole selected—namely, nine orally infected patients: three people living HIV and reactivation, five chronic recipients reactivation after organ transplantation one seronegative recipient kidney liver transplant from donor. Fifty-four archival samples (venous blood treated...
ObjectivesTrypanosoma cruzi reactivation in HIV patients is considered an opportunistic infection, usually with a fatal outcome. The aim of this study was to describe the epidemiological and clinical features T. infection compare these findings between without Chagas disease reactivation.MethodsThe medical records cruzi–HIV co-infected treated at Muñiz Infectious Diseases Hospital from January 2005 December 2014 were reviewed retrospectively. Epidemiological assessed compared...
T cell-mediated immune response plays a crucial role in controlling Trypanosoma cruzi infection and parasite burden, but it is also involved the clinical onset progression of chronic Chagas' disease. Therefore, study cells central to understanding against its implications for infected organism. The complexity parasite-host interactions hampers identification characterization cell-activating epitopes. We approached this issue by combining silico vitro methods interrogate patients'...
Abstract T cells are central to the adaptive immune response against Trypanosoma cruzi infection. In chronic Chagas disease (CCD), circulating parasite-specific memory show reduced functionality and increased expression of inhibitory receptors as a result persistent antigenic stimulation. This phenotype has been linked progression cardiac pathology, whereas presence polyfunctional shows association with therapeutic success. this study, we demonstrate that T. cruzi–specific human CD4+ can be...
Chagas disease is caused by the parasite Trypanosoma cruzi. In humans, it evolves into a chronic disease, eventually resulting in cardiac, digestive, and/or neurological disorders. present study, we characterized novel T. cruzi antigen named Tc323 (TcCLB.504087.20), recognized single-chain monoclonal antibody (scFv 6B6) isolated from B cells of patients with cardiomyopathy related to disease. Tc323, ~323 kDa protein, an uncharacterized protein showing putative quinoprotein alcohol...
The NHEPACHA Iberoamerican Network, founded on the initiative of a group researchers from Latin American countries and Spain, aims to establish research framework for Chagas disease that encompasses diagnosis treatment. For this purpose, network has created questionnaire gather relevant data epidemiological, clinical, diagnostic, therapeutic aspects disease. This was developed based consensus expert members network, with intention collecting high-quality standardized data, which can be used...
Antigen-specific T cells are central to the adaptive immune response against T. cruzi infection and underpin efficacy of on-going vaccine strategies. In this context, present study focuses on T-cell assays that define parasite-specificity basis upregulation TCR stimulation-induced surface markers. For purpose, we tested different dual marker combinations (OX40, CD25, CD40L, CD137, CD69, PD-L1, CD11a, CD49d, HLA-DR, CD38) reliably identify activated CD4+ CD8+ populations from PBMCs chronic...
Cyclophilins (CyPs) are a family of enzymes involved in protein folding. Trypanosoma cruzi, the causative agent Chagas disease, has 19-kDa cyclophilin, TcCyP19, that was found to be secreted parasite stages CL Brener clone and recognized by sera from T. cruzi-infected mice patients. The levels specific antibodies against TcCyP19 subjects before after drug treatment were measured an in-house enzyme linked immunosorbent assay (ELISA). Mice acute chronic phase infection, with successful...
Chagas disease reactivation in HIV-positive people is an opportunistic infection with 79 to 100% mortality. It commonly involves the central nervous system (CNS). Early treatment trypanocidal drugs such as benznidazole (BNZ) crucial for this severe manifestation of Trypanosoma cruzi infection. However, limited BNZ clinical pharmacology data are available, especially its concentration CNS. We report a series patients undergoing T. meningoencephalitis, their response, and cerebrospinal fluid...
Summary Trypanosoma cruzi , the aetiological agent of Chagas disease, has a highly efficient detoxification system to deal with oxidative burst imposed by its host. One antioxidant enzymes involved is cytosolic tryparedoxin peroxidase (c‐ TXNP x), which catalyses reduction hydrogen peroxide, small‐chain organic hydroperoxides and peroxynitrite. This enzyme present in all parasite stages, overexpression renders parasites more resistant defences macrophages, favouring survival. work addressed...
Summary Trypanosoma cruzi cytosolic tryparedoxin peroxidase (c‐TXNPx) is a 2‐Cys peroxiredoxin (Prx) with an important role in detoxifying host cell oxidative molecules during parasite infection. c‐TXNPx virulence factor, as its overexpression enhances infectivity and resistance to exogenous oxidation. As Prxs from other organisms possess immunomodulatory properties, we studied the effects of immune response analysed whether presence peroxidatic cysteine necessary mediate these properties....